staurosporine has been researched along with quizartinib in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.17) | 29.6817 |
| 2010's | 17 (70.83) | 24.3611 |
| 2020's | 6 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Chen, Z; Li, H; Lyu, J; Song, W; Sun, D; Xu, Y; Yang, Y; Zhao, Z; Zhou, W | 1 |
| Bao, J; Chen, P; Li, B; Li, H; Lu, S; Lu, T; Qin, T; Wang, Y; Yao, C; Zhi, Y | 1 |
| Abdel-Aziz, AK; Abouzid, KAM; Dokla, EME; McPhillie, MJ; Milik, SN; Minucci, S | 1 |
| Armstrong, RC; Belli, B; Bhagwat, SS; Brigham, D; Chao, Q; Cramer, MD; Gardner, MF; Gunawardane, RN; James, J; Karaman, MW; Levis, M; Pallares, G; Patel, HK; Pratz, KW; Sprankle, KG; Zarrinkar, PP | 1 |
| Levis, M; Murphy, KM; Pratz, KW; Rajkhowa, T; Sato, T; Stine, A | 1 |
| Chabner, BA; Fathi, AT | 1 |
| Cortes, J; Daver, N | 1 |
| Freeman, C; Giles, F; Swords, R | 1 |
| Böhmer, FD; Bolck, HA; Buchwald, M; Bug, G; Heinzel, T; Krämer, OH; Pietschmann, K; Polzer, H; Spiekermann, K; Spielberg, S | 1 |
| Albers, C; Duyster, J; Illert, AL; Leischner, H; Peschel, C; Verbeek, M; von Bubnoff, N; Yu, C | 1 |
| Galinsky, I; Gray, N; Griffin, JD; Liu, F; Liu, Q; Mitsiades, C; Nelson, E; Nicolais, M; Nonami, A; Sattler, M; Smith, RW; Stone, R; Weisberg, E; Zhang, J; Zhang, X | 1 |
| Berdel, WE; Blum, H; Bohlander, SK; Braess, J; Büchner, T; Dufour, A; Graf, A; Greif, PA; Herold, T; Hiddemann, W; Hopfner, KP; Kakadia, PM; Konstandin, NP; Krebs, S; Ksienzyk, B; Opatz, S; Polzer, H; Sauerland, MC; Schneider, S; Spiekermann, K; Vosberg, S; Woermann, BJ; Zellmeier, E | 1 |
| Lancet, JE | 1 |
| Brunner-Weinzierl, M; Fischer, T; Frey, S; Hebel, K; Heidel, FH; Höding, C; Isermann, B; Kliche, S; Lipka, DB; Mack, TS; Parkner, A; Perner, F; Pils, MC; Ranjan, S; Schnöder, TM; Schraven, B; Wagner, MC; Wolleschak, D | 1 |
| Andreeff, M; Cortes, J; Kantarjian, H; Pemmaraju, N; Ravandi, F | 1 |
| Antonakos, B; Barys, L; Cooke, VG; Cowens, K; Galinsky, I; Griffin, JD; Halilovic, E; Ito, M; Jeay, S; McDonough, SM; Nelson, E; Nonami, A; Ren, T; Sanda, T; Sattler, M; Simkin, I; Stone, R; Weisberg, E; Wiesmann, M; Wuerthner, JU; Yuan, J | 1 |
| Perl, AE | 1 |
| Adamia, S; Buhrlage, SJ; Case, AE; Dubreuil, P; Gokhale, PC; Gray, N; Griffin, JD; Letard, S; Liu, X; Meng, C; Sattler, M; Stone, RM; Tiv, HL; Wang, J; Weisberg, E; Yang, J | 1 |
| Antar, AI; Bazarbachi, A; Jabbour, E; Mohty, M; Otrock, ZK | 1 |
| Adamia, S; Buhrlage, SJ; Case, AE; Gokhale, PC; Gray, N; Griffin, JD; Liu, X; Meng, C; Sattler, M; Stone, R; Tiv, HL; Wang, J; Weisberg, E; Yang, J | 1 |
| Albors Ferreiro, M; Alonso Vence, N; Antelo Rodríguez, B; Bao Pérez, L; Bello López, JL; Cerchione, C; Cid López, M; Díaz Arias, JÁ; Ferreiro Ferro, R; González Pérez, MS; Martinelli, G; Mosquera Orgueira, A; Mosquera Torre, A; Peleteiro Raíndo, A; Pérez Encinas, MM | 1 |
| Bagnato, G; Cerchione, C; Giannini, MB; Marconi, G; Martinelli, G; Mosquera Orgueira, A; Musuraca, G; Simonetti, G | 1 |
| Abe, R; Maekawa, Y; Murata, T; Nishida, T; Niwa, M; Obata, Y; Okamoto, K; Shiina, I; Shimonaka, M; Suzuki, T; Tateyama, S; Yamawaki, K | 1 |
8 review(s) available for staurosporine and quizartinib
| Article | Year |
|---|---|
Molecular targeted therapy in acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; fms-Like Tyrosine Kinase 3; Humans; Janus Kinase 2; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; ras Proteins; Sorafenib; Staurosporine | 2012 |
Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.
Topics: Benzenesulfonates; Benzothiazoles; Carbazoles; CCAAT-Enhancer-Binding Protein-alpha; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Staurosporine | 2012 |
New agents: great expectations not realized.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Benzothiazoles; Cytosine; Gemtuzumab; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Naphthyridines; Phenylurea Compounds; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Staurosporine; Survival Analysis; Thiazoles; Treatment Failure; Vorinostat | 2013 |
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Imidazoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridazines; Sorafenib; Staurosporine | 2014 |
Availability of FLT3 inhibitors: how do we use them?
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzothiazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Sorafenib; Staurosporine | 2019 |
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; DNA Methylation; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Phenylurea Compounds; Piperidines; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome | 2020 |
FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; Drug Resistance, Multiple; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Forecasting; Furans; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Phenylurea Compounds; Piperidines; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Pyridazines; Recurrence; Sorafenib; Staurosporine | 2020 |
The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia.
Topics: Aniline Compounds; Antineoplastic Agents; Benzothiazoles; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Staurosporine | 2021 |
1 trial(s) available for staurosporine and quizartinib
| Article | Year |
|---|---|
Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia.
Topics: Adolescent; Adult; Amino Acid Substitution; Apoptosis; Base Sequence; Benzothiazoles; Cell Proliferation; Cell Transformation, Neoplastic; Core Binding Factor beta Subunit; Cytokines; DNA Mutational Analysis; Exome; Female; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Leukemic; Gene Rearrangement; Humans; Leukemia; Male; Middle Aged; Models, Molecular; Molecular Sequence Data; Mutation; Oncogene Proteins, Fusion; Phenylurea Compounds; Protein Kinase Inhibitors; Staurosporine | 2013 |
15 other study(ies) available for staurosporine and quizartinib
| Article | Year |
|---|---|
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Molecular Docking Simulation; Mutation; Phosphorylation; Protein Kinase Inhibitors; Pteridines | 2016 |
Discovery of the selective and efficacious inhibitors of FLT3 mutations.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Microsomes, Liver; Molecular Structure; Mutation; Protein Kinase Inhibitors; Structure-Activity Relationship | 2018 |
Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Receptor, trkA; Structure-Activity Relationship | 2022 |
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
Topics: Animals; Benzenesulfonates; Benzothiazoles; Bone Marrow; Carbazoles; Cell Line, Tumor; Cell Proliferation; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Prognosis; Protein Interaction Mapping; Protein Kinase C; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Staurosporine; Xenograft Model Antitumor Assays | 2009 |
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.
Topics: Alleles; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; Carbazoles; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib | 2010 |
FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.
Topics: Antineoplastic Agents; Benzothiazoles; Carbazoles; Clinical Trials as Topic; Cytokines; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Phenylurea Compounds; Pyrroles; Staurosporine; Sunitinib; Tandem Repeat Sequences | 2011 |
Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors.
Topics: Apoptosis; Benzothiazoles; Caspases; Cell Line; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Duplication; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid, Acute; Panobinostat; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Stability; Proteolysis; Signal Transduction; STAT5 Transcription Factor; Staurosporine | 2012 |
The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.
Topics: Antineoplastic Agents; Benzothiazoles; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Phenylurea Compounds; Pyrroles; Staurosporine; Sunitinib | 2013 |
Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells.
Topics: Apoptosis; Benzothiazoles; Bone Marrow Cells; Cell Communication; Cell Cycle; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Staurosporine; Stromal Cells | 2013 |
Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.
Topics: Benzothiazoles; fms-Like Tyrosine Kinase 3; Humans; Phenylurea Compounds; Staurosporine; T-Lymphocytes | 2014 |
Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Gene Expression; Humans; Inhibitory Concentration 50; Isoquinolines; Leukemia, Myeloid, Acute; Mice, Inbred NOD; Mice, SCID; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-mdm2; Staurosporine; Tumor Burden; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Cell Line, Tumor; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Mutant Proteins; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Proto-Oncogene Proteins c-kit; Pyrazines; Pyrazoles; Pyrroles; Sorafenib; Staurosporine; Triazines | 2019 |
Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazines; Sorafenib; Staurosporine; Syk Kinase | 2020 |
FLT3-ITD transduces autonomous growth signals during its biosynthetic trafficking in acute myelogenous leukemia cells.
Topics: Benzothiazoles; Cell Membrane; Cell Proliferation; Endoplasmic Reticulum; Extracellular Signal-Regulated MAP Kinases; fms-Like Tyrosine Kinase 3; Golgi Apparatus; Humans; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Mutation; Oncogenes; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; STAT5 Transcription Factor; Staurosporine; Tandem Repeat Sequences; THP-1 Cells; Tumor Suppressor Proteins | 2021 |